10th International Congress on Myeloproliferative Neoplasms (MPN) and Chronic Myeloid Leukemia (CML) : Diagnosis, Management and New Clinical Developments

10th International Congress on Myeloproliferative Neoplasms (MPN) and Chronic Myeloid Leukemia (CML) : Diagnosis, Management and New Clinical Developments is organized by Melton Medical Education, LLC and will be held during Nov 02 - 03, 2017 at InterContinental New York Times Square, New York, United States Of America.

The target audience for this medical event is for hematologists, medical oncologists, and other healthcare professionals (physicians, clinicians, physicians-in-training, oncology nurses, pharmacists, physician assistants, etc.) involved and/or interested in the therapeutic management of patients with myeloproliferative neoplasms and chronic myeloid leukemia. This CME Conference has been approved for a maximum of 11.25 AMA PRA Category 1 Credits.

Conference Objectives are :
• Describe underlying molecular and genetic events involved in myeloproliferative neoplasms and how these events could be utilized within the clinic.
• Evaluate the role of current therapies for the treatment of myelofibrosis, essential thrombocythemia and polycythemia vera.
• Assess how emerging data on treatment strategies for myeloproliferative neoplasms might affect current practice standards and how they might be appropriately incorporated into clinical practice to improve patient care.
• Describe the current treatment options and cost issues associated with routine care for CML patients.

Held biennially in the U.S. since 2001, this conference has become the premier forum for discussion on the latest advances in myeloproliferative neoplasms. The focus this year will be on the most recent updates and debates centered around the diagnosis and management of essential thrombocythemia (ET), polycythemia vera (PV), myelofibrosis (MF), chronic myelogenous leukemia (CML), and other related topics.

The program features a world class faculty and highly interactive sessions designed to engage participants and provide a state-of-the-art learning experience. At least 200 hematologists/oncologists and other healthcare professionals are expected to attend the two-day event, where they will have the opportunity to participate in a variety of educational formats including didactic sessions, patient case presentations and poster presentations, as well as multiple networking and one-on-one discussion opportunities.